[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know",
    "summary": "Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $416.96, moving -1.72% from the previous trading session.",
    "url": "https://finnhub.io/api/news?id=fbbfa4555ea0daf5036efb3fefa480d4b023c95ad313dd4747a395b9ec84bd96",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737068422,
      "headline": "Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know",
      "id": 132421522,
      "image": "https://media.zenfs.com/en/zacks.com/46ebfcbff417ac1bbde85ad33fa0d4be",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $416.96, moving -1.72% from the previous trading session.",
      "url": "https://finnhub.io/api/news?id=fbbfa4555ea0daf5036efb3fefa480d4b023c95ad313dd4747a395b9ec84bd96"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30?",
    "summary": "Vertex Pharmaceuticals (NASDAQ: VRTX) might be one of those special cases.  Should you buy Vertex stock hand over fist before Jan. 30?  Vertex built its business treating the underlying genetic cause of cystic fibrosis (CF), a rare disease that affects only around 109,000 patients worldwide.",
    "url": "https://finnhub.io/api/news?id=55f9e262c1982884920a22e9dff1a99d4f9c4ea47d951cf010e1f5079c107477",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737024540,
      "headline": "Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30?",
      "id": 132421524,
      "image": "https://g.foolcdn.com/editorial/images/803921/young-woman-looking-at-laptop.jpg",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (NASDAQ: VRTX) might be one of those special cases.  Should you buy Vertex stock hand over fist before Jan. 30?  Vertex built its business treating the underlying genetic cause of cystic fibrosis (CF), a rare disease that affects only around 109,000 patients worldwide.",
      "url": "https://finnhub.io/api/news?id=55f9e262c1982884920a22e9dff1a99d4f9c4ea47d951cf010e1f5079c107477"
    }
  },
  {
    "ts": null,
    "headline": "Next Century Growth Investors Q4 2024 Commentary",
    "summary": "In the fourth quarter of 2024, equity markets were positive and large cap stocks generally outperformed small cap stocks. Read more here.",
    "url": "https://finnhub.io/api/news?id=73e8069e54636e4d13a9d94bc0d115cbdc6cab07173db678464c129ad714ba43",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737008700,
      "headline": "Next Century Growth Investors Q4 2024 Commentary",
      "id": 132404982,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1305707642/image_1305707642.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "In the fourth quarter of 2024, equity markets were positive and large cap stocks generally outperformed small cap stocks. Read more here.",
      "url": "https://finnhub.io/api/news?id=73e8069e54636e4d13a9d94bc0d115cbdc6cab07173db678464c129ad714ba43"
    }
  }
]